Log inTry free

Rapport Therapeutics (RAPP) stock

Market cap $1.6B

$32.19
+0.06%

Market closed. Prices as of Monday's close.

Quality Score
-2
Poor
In its industry
#181of 300
Biotech

RAPP's Quality Score rose 1 point on Mon, Oct 5, to -2. Had its narrowest day in a week.

NextOct 2026“RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026”Trial data · 8-K, Aug 5

Follow RAPP's trial news. Pro members can get an alert when Rapport Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when RAPP files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

What's next for RAPP, and how long its cash lasts

From Rapport Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Oct 2026“RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026”Trial data · 8-K, Aug 5

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
RAP-219
Another trial
FOCUS 1Phase 3 · Recruiting · 333 people · main data estimated Jul 2029 · NCT07563881

3 more trials, 4 more milestones and 21 filings, for Pro members.

Cash runway

The company says its cash lasts into the second half of 2029 (8-K, Aug 5).

That is the company's own estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 10, 2026)
  • At-the-market share sales program (S-3ASR, filed Mar 10, 2026)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Operating Officer Cheryl Gault sold 10,000 shares on Sep 30, under a planned sale. 20 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Abraham Ceesay buys or sells

For Pro members: every trade, and Abraham Ceesay’s 15 filings and quotes.

Get an optional alert when RAPP files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why RAPP scores -2

PoorTrending up, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +2Chart checks 2 of 14 firing right now, one point each
  • −2Dilution 33.9% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Long-term trend adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on RAPP and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 2:09 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Thu Nov 5, before the open

After its last 4 reports it closed +0.6% on average, higher 2 of 4 times.

What would turn RAPP's score around: 8 things, for Pro members

Alert me when RAPP's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on RAPP and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

RAPP has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on RAPP, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1424.4

    Below 30.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 24 sessions ago.

  • 50-day average$43.33

    The price is 25.7% below it.

  • 200-day average$35.79

    The price is 10.1% below it. The 50-day is above the 200-day, since Aug 28, 2025.

  • ADX 1441.3

    25 or more, with +DI below -DI.

  • Support$31.58

    Swing low from Sep 24, 1.9% below the price.

  • Resistance$32.30

    Swing high from Mar 9, 0.3% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $28.66 to $48.11.

  • Volume0.4x

    Against its 20-day average, for the time of day.

How RAPP ranks in Biotech

RAPP is #181 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does RAPP report earnings, and what happens after?

Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 5, 2026Before open-1.8%+0.6%+15.7%
May 7, 2026Before open+1.2%+7.7%+2.8%
Mar 10, 2026Before open-4.4%-3.0%-9.6%
Nov 6, 2025Before open+1.3%-3.1%-3.8%

The gap is the next open against the close before the report; the reaction is where that session closed. RAPP closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

84 employeesBoston, MArapportrx.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of RAPP's score, with the points and the reason
  • All 14 checks on RAPP and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on RAPP
See all 14 checks on RAPPSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.